Pfizer (PFE)Director bought ~$999K

~$999K

Approx. value · 39K sh @ $25.46

67K

Holds after · shares reported

Traded

Aug 5, 2026

Filed

Aug 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 26, 2024CongressDisclosed sale of PFE — reported range $1,001 - $15,000
2. Mar 10, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
3. Mar 24, 2026CongressDisclosed sale of PFE — reported range $50,001 - $100,000
4. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
5. Jun 8, 2026CongressDisclosed sale of PFE — reported range $15,001 - $50,000
6. Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
7. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
8. Jun 24, 2026FDAFDA drug approval: Ibrance
9. Jun 24, 2026FDAFDA drug approval: Ibrance
10. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
11. Jul 20, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan
12. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
13. Aug 5, 2026 · this disclosureInsider · Largest insider buy since 2006Director purchased ~$999K of PFE shares in the open market

What came next

1. Aug 5, 2026Insider · 2 peopleInsiders: 1 purchase (~$960K), 1 sale (~$83K)
2. Aug 12, 2026Insider · Their first buy on recordCEO purchased ~$1M of PFE shares in the open market
3. Aug 21, 2026Government · Federal Register noticeAdvisory Committee; Oncologic Drugs Advisory Committee; Renewal
4. Sep 4, 2026FDARecall: Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC…
5. Sep 25, 2026Government · Federal Register noticeJeffrey Thies: Final Debarment Order
6. Oct 7, 2026FDAFDA drug approval: Tukysa

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Ronald E Blaylock, Director

• SEC Form 4 at Pfizer (PFE)Feb 14, 2025

The full history of Ronald E Blaylock, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pfizer

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its PFE page.